Octreotide Acetate CAS 83150-76-9 Peptide Puritas (HPLC) ≥98.0% API High Quality

Description:

Chemical Name: Octreotide Acetate

CAS: 83150-76-9

Aspectus: pulveris albi

Peptide Puritas (Per HPLC): ≥98.0%

Intende: 95%~ 105%

Acromegaly et Gastroenteropancreatic Tumors

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica acetatis Octreotide (CAS: 83150-76-9) cum qualitate princeps.Ruifu Chemical supplet seriem GMP peptides.Ruifu partus terrarum, quantitatis competitive pretium, parvas et parvas quantitates in promptu habere potest.Purchase Octreotide Acetate,Please contact: alvin@ruifuchem.com

Chemical Properties:

Nomen chemicum	Octreotide Acetate
Synonyma	SMS 201-995;Samilstin;Octreotide-LAR;
Sequences	D-Phe-c[Cys-Phe-D-Trp-Lys-Thr-Cys]
SMILES	[FCFWKTCT(Disulfide Bridge: Cys2-Cys7)]
CAS Number	83150-76-9
Stock Status	In Stock, Productio Ascendite usque ad chiliogrammata
Formulae hypotheticae	C49H66N10O10S2
M. Pondus	1019.24
Liquescens punctum	>140℃(dec.)
Density	1.39±0.10 g/cm3
Solubilitas	Solutum in acido acetico, DMSO et methanolo
Stabilitas	Hygroscopic
Repono Nativ.	Cool & Dry Place (2~8℃).leo
Documentum	COA, MS, HPLC, NMR, MSDS, etc.
Categoria	GMP Peptides
WGK Germania	3
Shipping Requirements	Sacculi, Desiccant Sacculi
Brand	Ruifu Chemical

Specifications:

Items	Signa inspectionis	Proventus
Aspectus	Alba pulveris	Alba pulveris
Solubilitas	Solutum in aqua seu 1% Acidum aceticum ad intentionem ≥1mg/ml ad da Serena Colorless SOLUTIO	Conforms
Amino Acidum Analysis (By HPLC)	Thr: 0.7~1.1	0.9
	Cys: 1.0~2.2	1.9
	Lys: 0.9~1.3	1.1
	Phe: 1.8~2.2	1.9
	Thr-OL: 0.6~1.3	0.9
	Trp: 0.4~1.1	0.8
Peptide Puritas (Per HPLC)	≥98.0% (per Area Integration)	99.81%
Substantiae cognatae (Per HPLC)	Totalis immunditias (%) ≤2.0%	0.19%
Substantiae cognatae (Per HPLC)	Impuritas maxima (%) ≤1.0%	0.12%
Acetate Content (HPLC)	5.0~12.8%	9.6%
Aqua Content (Carl Fischer)	≤7.0%	2.7%
TFA Content (Carl Fischer)	≤0.25%	0.13%
Imprimis Rotatione Optica	-45.0°～-55.0° (C=0.5, 95% HAc)	-51.5°
Assay	95.0 ~ 105.0% (Anhydrous, Acidum aceticum Free)	99.0%
Origin of Product	Synthetic
Operam	Tantum ad Research, non ad usum humanum
conclusio	Productum probatum & obsequitur cum specificationibus
Consuetudinem	GMP Peptides;Active Pharmaceutical Ingredient (API)

Sarcina & Repono:

Sarcina:Plastic phialam (pro stipare peptide dedicatam) vel phialam vitream, quantitas secundum exigentiam detail mos est.
Repono Condition:Condite in vasis obsignatis apud frigus et siccum (2~8℃) horreum ab substantiis incompossibilibus.A luce et humore protege.
Naviportans:Libera ad orbem terrarum per FedEx / DHL Express.Ieiunium et certas traditiones provide.

commoda:

FAQ:

Applicatio:

Octreotide acetate (Sandostatin) est synthetica peptidis analogum hormonum somatostatin, id est longum agens somatostatin analogum significatum propter symptomaticam potestatem in acromegaly et tumores gastroenteropancreaticos.Aliae potentiae usus inquisitionis includunt diabetes, psoriasis et morbum Alzheimer.Octreotide Acetate (Sandostatin) est synthetica peptidis analogum hormonis somatostatin.Actiones inhibitio secretionis pituitariae incrementi hormonum et inhibitio insulae pancreaticae cellae secretionis insulini et glucagonis.Dissimilis somatostatin, quae plasma media vita paucorum minutarum habet, Octreotide plasma eliminationis dimidium vitae 1 ad 2 horas habet.Excretio medicamentorum principaliter est renum.Octreotide minuit motum gastrointestinalem et inhibet contractionem vesicae fellis.

Peptide medicamenta Novartis Sandostatin (Acetes octreotide), est synthetica naturalis derivativa somatostatin octapeptidis, servat effectum pharmacologicum similem cum somatostatino, et effectus diuturnus.Indicationes pro acetate octreotide acromegaly includunt;Levatio symptomatum et signa cum neoplasia gastroenteropancreatica endocrinae functionis consociata;Et efficacia in tumoribus Carcinoideis exhibens syndrome carcinoidei, tumores VIP, et tumores glucagon.Acetate Octreotide praeterea gastrinomas/Zollinger-Ellison syndrome (plerumque in compositione cum inhibitoribus inhibitoribus sentinae vel H2 receptae obstructores), Insulinomas (praeoperativa hypoglycemia praeventionis et conservatio sanguinis saccharo normali), effectiva incrementi hormonum factor tumor solvens est. circiter L%.

Octreotide acetata est nationalis assecurationis Classis B medicamentum, quod est synthetica naturalis octapeptidis derivatio somatostatin, comparata cum somatostatin naturali, dimidia vita somatostatin manifesto diuturna et eosdem effectus pharmacologicos habet, inhibitione aucti muneris hormonis, inhibitionis. de acido gastrico, enzyme pancreatico, glucagono et secretione insulino, et reductione sanguinis viscerum, motility gastrointestinalis minui.Cum somatostatin nativo comparatus, octreotide longam vitam habet, magis selectiva est ad inhibitionem secretionis hormonis incrementi quam in inhibitione secretionis insulinae et hypersecretionem hormonum non reddit.1, Imperium chirurgiae seu radialis therapiae satis moderari morbos patientibus acromegaly symptomata non potest et incrementum hormonum (GH) insulinum sicut factor incrementi -1 (1GF-1) moderari.Sandostatin adhiberi potest etiam aegris acromegalys tractare, qui chirurgicam subire vel nolunt, vel aegros acromegaly, qui nondum therapiam radialem habuerant, aegros tractare.2. Levatio salubrium cum functionibus gastroenteropancreaticis (GEP) tumoribus endocrinis coniungitur sicut carcinoides tumores cum manifestationibus syndrome carcinoidei.Sandostatin medicamentum anti-cancri non est et hos aegros non sanat.III, Praeventionis complicationibus post chirurgicam pancreaticam.4, Hepatis cirrhosis cum haemorrhagia gastric-esophageali varicea sanguinis causata subitis curationibus, hemostasis et ne rebleedationis, Sandostatin componi debet cum sclerotherapy endoscopica et aliis curationibus specialibus.

83150-76-9 - Salus;

Effectus lateris huius producti sunt dolor abdominis, distentio abdominis, diarrhoea, steatorrhea;Gallstone formationis;Glucosa tolerantia minui, vel peior fieri in curatione prima, deinde emendari potest;Diu terminus applicationis sine productione endogenosa anticorporis nulla manifesta repercussio vel reactio adversa nulla fuit cum medicamento obstructum est vel celerius imminutum.2~8 grad C ad longum tempus reposita.